When was Orca Bio founded?

Orca Bio was founded in 2016 and became a unicorn in 2020, reaching the milestone in 4 years. It raised its 1st funding round 3 years after its incorporation.

Where is Orca Bio located?

Orca Bio is headquartered in Menlo Park, United States. It is registered at Menlo Park, California.

Who is the current CEO of Orca Bio?

Nathaniel fernhoff and Ivan Dimov s of Orca Bio. Ivan Dimov has also founded 1 company.

How many employees does Orca Bio have?

As of Sep 30, 2026, the latest employee count at Orca Bio is 384.

Is Orca Bio a funded company?

Orca Bio is a funded company, having raised a total of $300M across 2 funding rounds to date. The company's 1st funding round was a $192M Series D round, raised on Nov 29, 2019.

How much is Orca Bio worth?

The latest valuation of Orca Bio is $2.4B as of Jan 01, 2023.

When was the latest funding round of Orca Bio?

Orca Bio's latest funding was a $250M Series F round on Jan 09, 2026, with participation from 1 investor.

Is Orca Bio a Cell Therapy company?

The primary sectors of Orca Bio are Cell Therapy, Oncology, Immunology and Hematology.

Where does Orca Bio rank among its competitors?

Orca Bio ranks 15th amongst 495 active competitors, of which 170 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Orca Bio?

Orca Bio's top competitors include Sana Biotechnology, TScan Therapeutics and Tenaya Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Orca Bio - 2026 Company Profile, Team, Funding & Competitors

Orca Bio is a series F company based in Menlo Park (United States), founded in 2016 by Nathaniel fernhoff, Ivan Dimov and Jeroen Bekaert. It operates as a Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. Orca Bio has raised $300M in funding from Lightspeed Venture Partners, with a current valuation of $2.4B. The company has 495 active competitors, including 170 funded and 109 that have exited. Its top competitors include companies like Sana Biotechnology, TScan Therapeutics and Tenaya Therapeutics.

Sectors and market segments that Orca Bio operate in

Orca Bio serves in the Life Sciences market segments.The primary business model of Orca Bio are:

Company Details

Orca Bio is a developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. It uses OrcaSort technology that is an enabling feature for the scalability and high-precision of the manufacturing platform. It also helps in the isolation and purification of stem cells and immune cells used in hematopoietic cell grafts. The components of the technology are optimized for performance and designed to fit seamlessly into the clinical processing of apheresis products. It has developed therapeutic solutions for regulatory T cells that aims to temper the immune reaction. It reduces the fatal complications and provides maximum control of the development of the patient's new immune system.

Website: orcabio.com
Social
Email ID: *****@orcabio.com
Registered Address: Menlo Park, California

Key Metrics

Founded Year

2016

Location

Menlo Park, United States

Stage

Series F

Total Funding

$300M in 2 rounds

Latest Funding Round

Series F, Jan 09, 2026, $250M

Post Money Valuation

$2.4B as on Jan 01, 2023

Investors

Lightspeed Venture Partners & 12 more

Ranked

15^th among 495 active competitors

Employee Count

384 as on Sep 30, 2026

Similar Companies

Sana Biotechnology & 553 more

View Orca Bio's full profile

Orca Bio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Orca Biosystems, Inc. CIN: 47-5242464 , United States, Active	Oct 01, 2015	-	66 (As on Dec 31, 2021)	-
ORCA BIOSYSTEMS INC. CIN: 475242464 , United States, Active	Dec 26, 999	-	162 (As on Dec 31, 2024)	-

Orca Bio has raised a total funding of $300M over 2 rounds. Its first funding round was on Nov 29, 2019. Its latest funding round was a Series F round on Jan 09, 2026 for $250M. 1 investor participated in its latest round. Orca Bio has 13 institutional investors.

Here is the list of recent funding rounds of Orca Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 09, 2026	$250M	Series F	-	-	Lightspeed Venture Partners	-
Nov 29, 2019	$192M	Series D	-	-	Lightspeed Venture Partners	8VC, DCVC, ND Capital, IMRF, Kaiser Permanente, Mubadala

Access funding benchmarks and valuations. Sign up today!

View details of Orca Bio's funding rounds and investors

The founders of Orca Bio are Nathaniel fernhoff, Ivan Dimov and Jeroen Bekaert. Ivan Dimov is the CEO of Orca Bio.

Here are the details of Orca Bio's key team members:

Nathaniel fernhoff: Co-Founder & Co-CEO of Orca Bio and founder of 1 other company.
Contact Info: 1 email address
Ivan Dimov: Co-Founder & Co-CEO of Orca Bio.
Contact Info: 1 email address
Jeroen Bekaert: Co-Founder & COO of Orca Bio.
Contact Info: 1 email address

View details of Orca Bio's Founder profiles and Board Members

Orca Bio's employee count trend

Orca Bio has 384 employees as of Sep 26. Here is Orca Bio's employee count trend over the years:

Uncover Orca Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Orca Bio include Sana Biotechnology, TScan Therapeutics and Tenaya Therapeutics. Here is the list of Top 10 competitors of Orca Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
2nd	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
3rd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, Fidelity Investments & 7 others	70/100
4th	Viridian Therapeutics 2007, Boulder (United States), Public	Developer of medicines for patients with serious and rare diseases	$14.5M	Longitude Capital, Fairmount Funds Management ... & 2 others	69/100
5th	Autolus 2015, London (United Kingdom), Public	Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases	$181M	Syncona, 4Bio Capital & 7 others	65/100
6th	Ossium Health 2016, San Francisco (United States), Series C	Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning	$125M	Vivo Capital, CPMG & 12 others	65/100
7th	Rigel 1996, San Francisco (United States), Public	Developer of drugs for hematologic disorders, cancer, and rare immune disease	-	MidCap Financial, ProQuest Investments & 6 others	64/100
8th	Ajax 2019, Cambridge (United States), Acquired	Developer of targeted therapies for the treatment of hematologic malignancies	$135M	EcoR1, Goldman Sachs Asset Management & 8 others	64/100
9th	Sonoma Biotherapeutics 2012, San Francisco (United States), Series B	Developer of T-cell-based therapies for autoimmune and degenerative diseases	$335M	Lilly Asia Ventures, Octagon Capital Advisors ... & 20 others	64/100
10th	Cue Biopharma 2015, Cambridge (United States), Public	Precision immunotherapies to transform patients' lives by selectively modulating the immune system	$26.4M	MDB Capital	64/100
15th	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Mubadala, Felicis Ventures & 11 others	65/100